Characteristics of the study subjects
| Active CD | Active UC | Total | Remission CD | Remission UC | Total | Healthy subjects | |
|---|---|---|---|---|---|---|---|
| IBD | |||||||
| n (%) | 7 (17) | 16 (38) | 23 (55) | 5 (12) | 14 (33) | 19 (45) | 29 |
| Mean age (±SEM) | 37.6±19 | 36.0±14 | 37.0±15 | 42.1±19 | 37.5±12 | 38.7±14 | 34.6±14 |
| Male % | 43 | 44 | 43 | 40 | 64 | 58 | 38 |
| Montreal classification | |||||||
| L1 | 0 | – | 0 | 0 | – | 0 | – |
| L2 (%) | 7 (17) | – | 7 (17) | 5(12) | – | 5(12) | – |
| L3 | 0 | – | 0 | 0 | – | 0 | – |
| E1 (%) | – | 2 (5) | 2 (5) | – | 0 | 0 | – |
| E2 (%) | – | 6 (14) | 6 (14) | – | 4 (10) | 4 (10) | – |
| E3 (%) | – | 7 (17) | 7 (17) | – | 8 (17) | 8 (17) | – |
| Treatment | |||||||
| Corticosteroids (%) | 3 (7) | 8 (19) | 11(26) | 0 | 1 (2) | 1 (2) | – |
| Mesalazine (%) | 1 (2) | 5 (12) | 6 (14) | 1 (2) | 6 (14) | 7 (17) | – |
| Methotrexate (%) | 1 (2) | 3 (7) | 4 (10) | 0 | 0 | 0 | – |
| Purine analogues (%) | 1 (2) | 1 (2) | 2 (5) | 2 (5) | 5 (12) | 7 (17) | – |
| Infliximab (%) | 3 (7) | 7 (17) | 10 (24) | 2 (5) | 5 (12) | 7 (17) | – |
| Adalimumab (%) | 0 | 0 | 0 | 0 | 2 (5) | 2 (5) | – |
| Certolizumab (%) | 0 | 0 | 0 | 1 (2) | 0 | 1 (2) | |
| Ciclosporin (%) | 0 | 1 (2) | 1 (2) | 0 | 1 (2) | 1 (2) | – |
| Antibiotics | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CD, Crohn's disease; UC, ulcerative colitis.